Please note

Due to the recent spike in Covid-19 cases, we are no longer able to entertain walk-in visits to our headquarters or any of our facilities.

Cefrin powder for injection

Dexa Medica

Product packaging may vary from one country to another.

Ingredients in every vial

Cefpirome 1 g

Each package contains

1 vial of 1 g

Other details

Dosage formPowder for Injection
Flavour None

W.H.O. classification

ATC Level 1 J – Antiinfectives for systemic use
ATC Level 2 J01 – Antibacterials for Systemic Use
ATC Level 3 J01D – Other Beta-Lactam Antibacterials in ATC

Warnings

Pregnancy

<span class="warning-0 warning-pregnancy">NOT RECOMMENDED</span>This item is not safe for use during pregnancy.

Lactation

NOT RECOMMENDEDThis item is not safe for use during lactation.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

0 TO 12 YEARS OLD
Clinical data for children <12 years of age is insufficient. Therefore, cefpirome should not be used for this age group. 18 YEARS OLD AND ABOVE
The following dosages are recommended for moderate to severe infections in patients with normal renal function:

Complicated upper and lower urinary tract infections
– Unit dose: 1 g
– Dosage intervals: 12 hours
– Total daily dose: 2 g

Skin and soft tissue infections
– Unit dose: 1 g
– Dosage intervals: 12 hours
– Total daily dose: 2 g

Lower respiratory tract infections
– Unit dose: 1 to 2 g
– Dosage intervals: 12 hours
– Total daily dose: 2 to 4 g

Bacteremia/septicemia
– Unit dose: 2 g
– Dosage intervals: 12 hours
– Total daily dose: 4 g

Infections in neutropenic patients
– Unit dose: 2 g
– Dosage intervals: 12 hours
– Total daily dose: 4 g

Severe infections
– Unit dose: 2 g
– Dosage intervals: 12 hours
– Total daily dose: 4 g

For urinary tract and skin and soft tissue infections, the unit dose may be increased to 2 g in very severe cases.

65 YEARS OLD AND ABOVE
No adjustment is required unless renal impairment is present.

PATIENTS WITH IMPAIRED RENAL FUNCTION
Cefpirome is excreted principally by the kidney. The dose must therefore be reduced in patients with impaired renal function to compensate for the slower excretion. The recommended dosages are:

CrCl 20-50 ml/minute:
Initial dose 1 g, maintenance dose 0.5 g twice daily
Initial dose 2 g, maintenance dose 1 g twice daily

CrCl 5-20 ml/minute:
Initial dose 1 g, maintenance dose 0.5 g once daily
Initial dose 2 g, maintenance dose 1 g once daily

CrCl ˂5 ml/minute (in hemodyalysis patients)
Initial dose 1 g, maintenance dose 0.5 g once daily ± 0.25 g immediately after dialysis
Initial dose 2 g, maintenance dose 1 g once daily ± 0.5 g immediately after dialysis

Indication

For infection treatment, whether before the causative organism is known or infections caused by bacterial organisms sensitive to cefpirome.
– Lower respiratory tract infections (bronchopneumonia, lobar pneumonia)
– Complicated upper (pyelonephritis) and lower urinary tract infections
– Skin and soft tissue infections (cellulitis, skin abscess and infected wound)
– Infections in neutropenic patients
– Bacteremia/septicemia
– Severe infections